{"filings":[{"id":96556,"accession_number":"0001104659-26-057226","cik":1888886,"company_name":"Structure Therapeutics Inc.","ticker":"GPCR","form_type":"8-K","filed_at":"2026-05-07T23:59:59+00:00","items":["1.01","2.02","8.01","9.01"],"status":"ready","headline":"Structure Therapeutics Amends Sales Agreement to Raise ATM Capacity to $400M and Reports Q1 2026 Financials","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Amended and restated Sales Agreement with Leerink Partners and Cantor Fitzgerald to remove aggregate offering limit and filed prospectus supplement increasing ATM by $150M to $400M.","Aleniglipron Phase 2 ACCESS II achieved placebo-adjusted weight loss of 16.3% (39 lbs) at 180 mg and 16.0% (37 lbs) at 240 mg at 44 weeks.","Cash, cash equivalents and short-term investments totaled $1.5 billion as of March 31, 2026; received $100M upfront license fee in Q1.","FDA provided positive end-of-Phase 2 feedback; Phase 3 program for aleniglipron expected to initiate in Q3 2026.","Net loss for Q1 2026 was $76.0 million, including $11.6 million non-cash share-based compensation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":2810081505.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":96555,"accession_number":"0001104659-26-043425","cik":1888886,"company_name":"Structure Therapeutics Inc.","ticker":"GPCR","form_type":"8-K","filed_at":"2026-04-15T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Structure Therapeutics appoints Matthew Lang as COO and General Counsel","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Lang effective April 15, 2026; salary $560,000/yr with 40% target bonus.","Equity grant: options for 223,776 ordinary shares (74,592 ADSs), time-based RSUs for 184,614 ordinary shares, and PSUs for 46,155 ordinary shares at target.","Former Chief Legal Officer at Metsera, where he helped guide the up to $10B Pfizer acquisition; also held exec roles at Lyell, Myovant, and Gilead.","Company advancing aleniglipron into Phase 3 for obesity; Lang to support operational foundation and strategic priorities."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":2810081505.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":110563,"accession_number":"0001104659-26-028023","cik":1888886,"company_name":"Structure Therapeutics Inc.","ticker":"GPCR","form_type":"8-K","filed_at":"2026-03-16T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Positive Phase 2 data: oral GLP-1 aleniglipron achieves up to 16.3% placebo-adjusted weight loss at 44 weeks","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Placebo-adjusted mean weight loss 16.3% at 180 mg and 16.0% at 240 mg (p<0.0001) at 44 weeks.","OLE study shows continued weight loss up to 16.2% at 56 weeks; no plateau observed.","Lower 2.5 mg starting dose improves tolerability; AE-related discontinuations 2-3.4% in interim OLE / body composition studies.","End-of-Phase 2 meeting with FDA scheduled Q2 2026; Phase 3 initiation on track for 2H 2026.","No drug-induced liver injury, no persistent liver enzyme elevations, no QTc prolongation across >625 participants."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":2810081505.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":110562,"accession_number":"0001104659-26-020494","cik":1888886,"company_name":"Structure Therapeutics Inc.","ticker":"GPCR","form_type":"8-K","filed_at":"2026-02-26T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Structure Therapeutics posts Q4 net income; aleniglipron up to 15.3% weight loss in Phase 2","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2025 net income $33.0M vs. net loss of $36.5M in Q4 2024; full-year net loss $141.2M.","Cash, equivalents and investments $1.4B as of Dec 31, 2025, funding through end of 2028.","Aleniglipron Phase 2 ACCESS II: placebo-adjusted weight loss up to 15.3% with 240 mg at 36 weeks.","Phase 3 for aleniglipron expected in H2 2026; topline 44-week data from ACCESS II due Q1 2026.","Oral amylin agonists: ACCG-2671 in Phase 1; ACCG-3535 to enter Phase 1 in H2 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.8,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":2810081505.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":110561,"accession_number":"0001104659-26-000620","cik":1888886,"company_name":"Structure Therapeutics Inc.","ticker":"GPCR","form_type":"8-K","filed_at":"2026-01-05T23:59:59+00:00","items":["1.01"],"status":"ready","headline":"Structure Therapeutics licenses GLP-1 patents to Genentech for $100M upfront","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gasherbrum Bio (Structure sub) grants non-exclusive license to Genentech/Roche for CT-996 GLP-1 RA.","Genentech pays $100M one-time non-refundable fee within 30 days; plus low single-digit royalties.","License covers patents distinct from aleniglipron; Structure's own GLP-1/dual agonist programs unaffected.","Either party may terminate for uncured material breach; Gasherbrum can terminate if GNE challenges patents."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":2810081505.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":127179,"accession_number":"0001104659-25-120015","cik":1888886,"company_name":"Structure Therapeutics Inc.","ticker":"GPCR","form_type":"8-K","filed_at":"2025-12-10T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Structure Therapeutics launches $650M follow-on offering of ADSs and pre-funded warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds ~$650M from 8.46M ADSs at $65.00 and 1.54M pre-funded warrants at $64.9999.","Underwriters include Jefferies, Leerink, Goldman Sachs, Morgan Stanley; 30-day option for 1.5M additional ADSs.","Closing expected Dec 11, 2025; pre-funded warrants have 9.99% beneficial ownership limit (can increase to 19.99%).","Offering made under effective shelf registration; proceeds before underwriting discounts and expenses."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":2810081505.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":127178,"accession_number":"0001104659-25-119095","cik":1888886,"company_name":"Structure Therapeutics Inc.","ticker":"GPCR","form_type":"8-K","filed_at":"2025-12-08T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Structure Therapeutics reports positive Phase 2 data for oral GLP-1 aleniglipron; plans Phase 3 by mid-2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Placebo-adjusted mean weight loss of 11.3% (27.3 lbs) at 120 mg in Phase 2b ACCESS study; up to 15.3% (35.5 lbs) at 240 mg in exploratory ACCESS II.","No AE-related discontinuations when starting at 2.5 mg in OLE and body composition studies, improving tolerability vs 5 mg start.","No cases of drug-induced liver injury, persistent liver enzyme elevations, or QTc prolongation across all aleniglipron studies.","Plans to request Type B End-of-Phase 2 meeting with FDA in H1 2026; Phase 3 program initiation expected by mid-2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":2810081505.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":127177,"accession_number":"0001104659-25-107740","cik":1888886,"company_name":"Structure Therapeutics Inc.","ticker":"GPCR","form_type":"8-K","filed_at":"2025-11-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Structure Therapeutics reports Q3 net loss $65.7M; aleniglipron data on track for year-end 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $65.7M in Q3 2025 vs. $34.0M in Q3 2024; R&D expenses rose to $59.0M from $32.6M.","Cash, cash equivalents and short-term investments totaled $799.0M as of Sep 30, 2025, expected to fund operations through at least 2027.","Topline 36-week data from aleniglipron ACCESS and ACCESS II Phase 2 studies expected by year-end 2025.","Phase 1 study of oral amylin receptor agonist ACCG-2671 anticipated by year-end 2025; second amylin candidate ACCG-3535 declared.","GAAP net loss per share not disclosed; non-cash share-based compensation was $7.5M in Q3 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.0,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":2810081505.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":143974,"accession_number":"0001104659-25-074712","cik":1888886,"company_name":"Structure Therapeutics Inc.","ticker":"GPCR","form_type":"8-K","filed_at":"2025-08-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Structure Therapeutics reports Q2 net loss $61.7M; cash $786.5M; aleniglipron data on track for year-end 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $61.7M vs $26.0M YoY; R&D expenses $54.7M (up from $22.1M) due to advancing GLP-1 program.","Cash, equivalents, and short-term investments $786.5M; expected to fund operations through at least 2027.","Topline data from aleniglipron ACCESS and ACCESS II studies on track for year-end 2025 readouts.","Three new aleniglipron studies initiated: maintenance switching, body composition, T2DM, with enrollment Q3/Q4 2025.","ACCG-2671 (oral amylin) Phase 1 initiation planned by year-end 2025; preclinical data presented."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.63,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":2810081505.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":162258,"accession_number":"0001104659-25-062576","cik":1888886,"company_name":"Structure Therapeutics Inc.","ticker":"GPCR","form_type":"8-K","filed_at":"2025-06-25T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Structure Therapeutics shareholders elect directors, ratify auditor at 2025 AGM","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Eric Dobmeier and Joanne Waldstreicher elected as Class II directors (133.7M and 131.4M votes for).","Ernst & Young LLP ratified as independent auditor for FY2025 (134.3M votes for).","Advisory vote on named executive officer compensation approved (115.0M for, 19.2M against).","Shareholders selected annual frequency for future say-on-pay votes (133.6M votes for 1-year)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":2810081505.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":162257,"accession_number":"0001104659-25-046149","cik":1888886,"company_name":"Structure Therapeutics Inc.","ticker":"GPCR","form_type":"8-K","filed_at":"2025-05-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Structure Therapeutics Q1 net loss $46.8M; cash $836.9M; aleniglipron Ph2b data expected by year-end","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $46.8M in Q1 2025 vs $26.0M in Q1 2024; R&D expenses $42.9M (up from $20.7M).","Cash, equivalents and short-term investments $836.9M as of March 31, 2025; funding through at least 2027.","Phase 2b ACCESS and ACCESS II fully enrolled; topline 36-week data for aleniglipron expected by year-end 2025.","Initiation of Phase 1 study for oral amylin agonist ACCG-2671 planned by year-end 2025; new preclinical data at ADA June 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.27,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":2810081505.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":180275,"accession_number":"0001104659-25-018275","cik":1888886,"company_name":"Structure Therapeutics Inc.","ticker":"GPCR","form_type":"8-K","filed_at":"2025-02-27T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Structure Therapeutics: aleniglipron studies fully enrolled; Q4 net loss $36.5M, cash $883.5M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["ACCESS and ACCESS II studies fully enrolled on schedule; topline 36-week data expected by year-end 2025.","Cash, cash equivalents and short-term investments $883.5M as of Dec 31, 2024; expected to fund operations through 2027.","Net loss Q4 2024 $36.5M ($24.5M Q4 2023); FY2024 net loss $122.5M ($89.6M FY2023).","Oral amylin agonist ACCG-2671: IND-enabling activities underway; Phase 1 initiation expected by year-end 2025.","R&D expenses increased to $33.5M for Q4 2024 from $20.0M; full year $108.8M from $70.1M."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.78,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":2810081505.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":197072,"accession_number":"0001104659-24-129378","cik":1888886,"company_name":"Structure Therapeutics Inc.","ticker":"GPCR","form_type":"8-K","filed_at":"2024-12-17T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Structure Therapeutics selects lead oral amylin agonist ACCG-2671 for obesity; Phase 1 start by end-2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["ACCG-2671 is a Dual Amylin and Calcitonin Receptor Agonist (DACRA) designed for once-daily oral dosing.","Preclinical data show cagrilintide-like efficacy with potent target engagement and favorable safety profile.","Phase 1 clinical development expected to begin by year end 2025.","Company believes ACCG-2671 could serve as backbone therapy for fixed-dose oral combinations with GLP-1 candidate GSBR-1290.","Structure is developing a series of amylin-based candidates using its GPCR structure-based drug discovery platform."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":2810081505.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":197071,"accession_number":"0001104659-24-117691","cik":1888886,"company_name":"Structure Therapeutics Inc.","ticker":"GPCR","form_type":"8-K","filed_at":"2024-11-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Structure Therapeutics reports Q3 2024 net loss of $34M; first patients dosed in Phase 2b ACCESS obesity study","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash, cash equivalents and short-term investments $915.3M; expected to fund operations through at least 2027 excluding Phase 3 registrational studies.","Net loss $34.0M for Q3 2024 vs $23.9M in Q3 2023; R&D expenses $32.6M (up from $17.5M) driven by GLP-1R program advancement.","First patients dosed in Phase 2b ACCESS study of GSBR-1290 for obesity; topline data expected Q4 2025.","Oral amylin receptor agonist development candidate expected by end of 2024; GIPR candidate expected H1 2025.","ANPA-0073 (APJR agonist) Phase 2 ready; long-term toxicology studies ongoing, expected completion in 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.56,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":2810081505.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":213339,"accession_number":"0001104659-24-100668","cik":1888886,"company_name":"Structure Therapeutics Inc.","ticker":"GPCR","form_type":"8-K","filed_at":"2024-09-17T23:59:59+00:00","items":["5.02","7.01","8.01","9.01"],"status":"ready","headline":"Structure Therapeutics appoints Blai Coll as CMO, Ashley Hall as CDO; Mark Bach departs in planned succession","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Mark Bach to depart as CMO effective Sept 18; will serve as advisor through Dec 31.","Blai Coll, previously VP of Clinical Development, promoted to CMO effective Sept 18.","Ashley Hall appointed as newly created Chief Development Officer role.","GSBR-1290 Phase 2b for obesity planned for Q4 2024.","Dr. Coll led GSBR-1290 program; Ms. Hall brings regulatory experience from Repatha."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":2810081505.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":213338,"accession_number":"0001104659-24-093434","cik":1888886,"company_name":"Structure Therapeutics Inc.","ticker":"GPCR","form_type":"8-K","filed_at":"2024-08-27T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Structure Therapeutics appoints Angus Russell to Board, Audit Committee","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Angus Russell appointed Class I director effective Aug 26, 2024; term expires at 2027 annual meeting.","Russell joins Audit Committee; Ted Love, M.D. transitioned off the Audit Committee.","Granted option for 75,000 ordinary shares (25,000 ADS) vesting over 36 months.","Annual cash retainers: $45,000 for Board service plus $10,000 for Audit Committee, prorated for 2024.","Board determined Russell independent under Nasdaq standards and meets audit committee requirements."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":2810081505.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":213337,"accession_number":"0001104659-24-087275","cik":1888886,"company_name":"Structure Therapeutics Inc.","ticker":"GPCR","form_type":"8-K","filed_at":"2024-08-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Structure Therapeutics Q2 net loss $26M; cash $927M; GSBR-1290 Phase 2b on track Q4 2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 2024 net loss $26.0M vs $23.3M in Q2 2023; R&D expenses $22.1M, G&A $11.3M.","Cash, equivalents and short-term investments $927.1M expected to fund operations through at least 2027.","GSBR-1290 Phase 2b obesity study on track to initiate in Q4 2024; Phase 2a showed 6.2% placebo-adjusted weight loss at 12 weeks.","Amylin receptor agonist development candidate expected to be selected in Q4 2024; GIPR candidate expected H1 2025.","Phase 1 trial of LTSE-2578 (LPA1R antagonist for IPF) initiated in June 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.36,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":2810081505.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":232535,"accession_number":"0001104659-24-075724","cik":1888886,"company_name":"Structure Therapeutics Inc.","ticker":"GPCR","form_type":"8-K","filed_at":"2024-06-27T23:59:59+00:00","items":["5.07","8.01"],"status":"ready","headline":"Structure Therapeutics elects Sharon Tetlow to board; Ted Love joins audit committee","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Sharon Tetlow elected as Class I director for 3-year term with 117.2M votes for, 12.6M against.","Shareholders ratified Ernst & Young as independent auditor for FY2024 (129.9M for, 32k against).","Ted W. Love, M.D. appointed to Audit Committee effective June 25, 2024.","Audit Committee now consists of Sharon Tetlow, Eric Dobmeier, and Dr. Love."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":2810081505.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":232534,"accession_number":"0001104659-24-067836","cik":1888886,"company_name":"Structure Therapeutics Inc.","ticker":"GPCR","form_type":"8-K","filed_at":"2024-06-03T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Structure Therapeutics updates risk factors and GLP-1 agonist market data in 8-K filing","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Updated disclosure: six GLP-1R agonists generated ~$35.9B in 2023 sales, projected to reach $85.9B by 2027.","Added risk factors include NHP shortage, BIOSECURE Act potential impact on WuXi STA supply, and clinical trial risks.","Phase 2a obesity cohort for GSBR-1290 showed 6.2% placebo-adjusted weight loss at 12 weeks in June 2024.","Company plans to submit IND for Phase 2b chronic weight management study of GSBR-1290 in Q3 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":2810081505.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":232533,"accession_number":"0001104659-24-067483","cik":1888886,"company_name":"Structure Therapeutics Inc.","ticker":"GPCR","form_type":"8-K","filed_at":"2024-06-03T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Structure Therapeutics reports positive Phase 2a data for obesity drug GSBR-1290","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["GSBR-1290 achieved placebo-adjusted mean weight loss of 6.2% (p<0.0001) in Phase 2a obesity study at 12 weeks.","Capsule to tablet PK study showed up to 6.9% placebo-adjusted weight loss (p<0.0001) with new tablet formulation.","67% of GSBR-1290 treated participants achieved ≥6% weight loss and 33% ≥10% loss vs 0% for placebo.","Adverse events were GI-related; discontinuations 5% in Phase 2a and 11% in PK study; no liver injury.","Phase 2b obesity study expected to begin Q4 2024 with ~300 participants using tablet formulation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":2810081505.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":232532,"accession_number":"0001104659-24-059329","cik":1888886,"company_name":"Structure Therapeutics Inc.","ticker":"GPCR","form_type":"8-K","filed_at":"2024-05-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Structure Therapeutics reports Q1 net loss $26M; GSBR-1290 Phase 2a obesity data due June 2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $26.0M in Q1 2024 vs $18.0M in Q1 2023; cash $436.4M funds projected operations through at least 2026.","Topline GSBR-1290 Phase 2a obesity 12-week data for 40 participants expected June 2024; Phase 2b obesity study to start Q4 2024.","R&D expenses $20.7M (+58% YoY) driven by GLP-1R franchise; G&A expenses $11.3M (+74% YoY) from public company infrastructure.","Plan to initiate first-in-human Phase 1 trial of LTSE-2578 (oral LPA1R antagonist for IPF) in June 2024.","Amylin candidate selection expected Q4 2024; GIPR candidate selection H1 2025; ANPA-0073 (APJR) Phase 1 completed."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.19,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":2810081505.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":250796,"accession_number":"0001104659-24-032121","cik":1888886,"company_name":"Structure Therapeutics Inc.","ticker":"GPCR","form_type":"8-K","filed_at":"2024-03-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Structure Therapeutics Q4 net loss $24.5M; cash $467.3M; Phase 2a data due Q2 2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss for Q4 2023 was $24.5M ($89.6M full year); compared to $11.9M in Q4 2022.","Cash and equivalents $467.3M at year-end; expected to fund operations through 2026.","Topline GSBR-1290 Phase 2a obesity data (12-week) expected latter half of Q2 2024.","Phase 2b obesity study of GSBR-1290 planned to start Q4 2024.","R&D expenses $20.0M in Q4 2023 ($70.1M full year), up from $8.4M in Q4 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":2810081505.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}